home
Number
Title
Author
Date
159
HLB Life Sciences Secures Exclusive Rights for Only FDA-Approved Vitamin C Injection in Korea and Japan
admin
2024.07.23
158
HLB Global acquires Barabio to jump into digital healthcare biz
admin
2024.07.10
157
HLB Panagene Expands Diagnostics Portfolio, Targets Global Market with Subsidiary BioSquare
admin
2024.07.05
156
HLB concludes FDA meeting regarding factory inspection: “No further supplements needed”
admin
2024.07.05
155
HLB bioStep Unveils Global Expansion Plans
admin
2024.06.18
154
ASCO 2024: HLB's Rivoceranib Plus Camrelizumab Attracts a Liver Cancer Experts
admin
2024.06.04
153
HLB Announces Promising Liver Cancer Treatment Results at ASCO 2024
admin
2024.06.03
152
HLB Subsidiaries Showcased Cancer Research Progress at AACR 2024
admin
2024.05.16
151
EMA Grants Paediatric Investigation Plan Waiver for HLB's Rivoceranib
admin
2024.05.16
150
HLB bioStep acquires GLP toxicology testing firm Croen
admin
2024.04.26